José de Brito Vieira Neto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
José de Brito Vieira Neto has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Pessoa
Universidade Federal do Ceará, Brasil
4 shared publications - Maria Claudia dos Santos Luciano
Ceara Cancer Institute Fortaleza Brazil
2 shared publications - Paulo Roberto Ribeiro Costa
Laboratório de Química Bioorgânica (LQB), Instituto de Pesquisa de Produtos Naturais Walter Mors, Universidade Federal do Rio de Janeiro, 21941-902, Rio de Janeiro, Brazil
2 shared publications - Sarah Leyenne Alves Sales
Postgraduate Program in Physiology and Pharmacology, Drug Research and Development Center (NPDM), Federal University of Ceara (UFC), Fortaleza, Brazil
2 shared publications - Alexsandra Fernandes Pereira
Laboratory of Animal Biotechnology Federal Rural University of Semi‐Arid Mossoro Brazil
1 shared publication Aline Kimberly Almeida Rodrigues
Hospital Haroldo Juaçaba, Ceará Cancer Institute, Fortaleza, Brazil
1 shared publication
Latest Publications
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Concise Enantioselective Synthesis of the Antimitotic (+)-2,3,9-Trimethoxypterocarpan via Asymmetric Transfer Hydrogenation
(+)-2,3,9-Trimethoxypterocarpan [(+)-PTC] is a naturally occurring isoflavonoid that exhibits potent antitumor activity, putatively acting through the inhibition of kinesin-5 (Eg5), a mechanism distinct from classic tubulin-targeting agents. However, its preclinical development has been severely hampered by supply limitations, as previous synthetic routes relied on inefficient racemic strategies requiring laborious chiral resolution. Herein, we report a concise, biomimetic, and enantioselective total synthesis of (+)-PTC that overcomes these challenges. The route features a robust ligand-free Suzuki cross-coupling in PEG-400 and utilizes a ruthenium-catalyzed asymmetric transfer hydrogenation coupled with dynamic kinetic resolution (ATH-DKR) as the key stereodefining step. Optimized conditions enabled the scale-up of the key reduction with a low catalyst loading (2 mol%), delivering the pterocarpan core with high optical purity (98% ee) and excellent diastereocontrol. The synthesis was completed in just six steps with 64% overall yield, securing a sustainable supply of the bioactive enantiomer for advanced biological validation and providing divergent access to optically pure isoflavanone analogues.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Concise Enantioselective Synthesis of the Antimitotic (+)-2,3,9-Trimethoxypterocarpan via Asymmetric Transfer Hydrogenation
(+)-2,3,9-Trimethoxypterocarpan [(+)-PTC] is a naturally occurring isoflavonoid that exhibits potent antitumor activity, putatively acting through the inhibition of kinesin-5 (Eg5), a mechanism distinct from classic tubulin-targeting agents. However, its preclinical development has been severely hampered by supply limitations, as previous synthetic routes relied on inefficient racemic strategies requiring laborious chiral resolution. Herein, we report a concise, biomimetic, and enantioselective total synthesis of (+)-PTC that overcomes these challenges. The route features a robust ligand-free Suzuki cross-coupling in PEG-400 and utilizes a ruthenium-catalyzed asymmetric transfer hydrogenation coupled with dynamic kinetic resolution (ATH-DKR) as the key stereodefining step. Optimized conditions enabled the scale-up of the key reduction with a low catalyst loading (2 mol%), delivering the pterocarpan core with high optical purity (98% ee) and excellent diastereocontrol. The synthesis was completed in just six steps with 64% overall yield, securing a sustainable supply of the bioactive enantiomer for advanced biological validation and providing divergent access to optically pure isoflavanone analogues.
- Open Access
- 21 April 2025
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 3, 1008107
Synthesis and antitumoral activity of novel biaryl hydroxy-triazole and fluorene-triazole hybrids
Aim: The development of selective and potent antitumor agents remains a significant challenge. This study aimed to synthesize and evaluate biaryl hydroxy-1,2,3-triazoles and 9H-fluorene-1,2,3-triazole hybrids, inspired by previously identified bioactive 1,2,3-triazoles, for their cytotoxic potential against human cancer cell lines. Methods: A library of 13 biaryl hydroxy-1,2,3-triazoles and 11 fluorene-1,2,3-triazoles was synthesized using optimized Suzuki and telescopic one-pot reactions, with yields ranging from 16% to 97%. The cytotoxicity of these compounds was tested against HCT-116 (colorectal cancer), SNB-19 (astrocytoma), MDA-MB-231 (triple-negative breast cancer), and MOLM-13 (acute myeloid leukemia, FLT3-ITD mutant) cell lines. Results: Two fluorene-triazoles, 1-(2-bromophenyl)-4-(9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO258) and 1-(4-bromophenyl)-4-(2-fluoro-9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO272), both containing bromine substituents, exhibited selective cytotoxicity against MOLM-13, with half-maximal inhibitory concentration (IC50) values of 25.5 μM and 12.5 μM, respectively. Furthermore, LSO258 and LS0272 showed a selectivity index ≥ 2 towards the MOLM-13 cell line. Biaryl hydroxy-1,2,3-triazoles displayed broader activity, with [1,1’-biphenyl]-2-yl(1-(2,5-dibromophenyl)-1H-1,2,3-triazol-4-yl)methanol (LSO278), featuring two bromine groups, demonstrating potency across HCT-116, MDA-MB-231, and MOLM-13 (IC50: 23.4 μM, 34.3 μM, and 18.7 μM, respectively). However, structural rigidity did not consistently predict activity, as 1-(2,5-dibromophenyl)-4-(9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO275), a rigid fluorene-triazole, was inactive. MOLM-13 was the most sensitive cell line, with compounds such as 4-(9H-fluoren-9-yl)-1-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazole (LSO259) and (1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)(4’-fluoro-[1,1’-biphenyl]-2-yl)methanol (LSO280), achieving maximum growth inhibition (MGI > 55%) despite not reaching IC50 values. Conclusions: The results highlight the critical role of bromine substitution on the aryl azide-derived ring in modulating cytotoxic activity. The study reinforces the potential of rigid fluorene-based scaffolds as promising leads for the development of targeted therapies against FLT3-mutant leukemia, aligning with previous reports on 1,2,3-triazole hybrids antiproliferative activity in leukemia models.
- 21 April 2025
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 3, 1008107
Open AccessSynthesis and antitumoral activity of novel biaryl hydroxy-triazole and fluorene-triazole hybrids
Aim: The development of selective and potent antitumor agents remains a significant challenge. This study aimed to synthesize and evaluate biaryl hydroxy-1,2,3-triazoles and 9H-fluorene-1,2,3-triazole hybrids, inspired by previously identified bioactive 1,2,3-triazoles, for their cytotoxic potential against human cancer cell lines. Methods: A library of 13 biaryl hydroxy-1,2,3-triazoles and 11 fluorene-1,2,3-triazoles was synthesized using optimized Suzuki and telescopic one-pot reactions, with yields ranging from 16% to 97%. The cytotoxicity of these compounds was tested against HCT-116 (colorectal cancer), SNB-19 (astrocytoma), MDA-MB-231 (triple-negative breast cancer), and MOLM-13 (acute myeloid leukemia, FLT3-ITD mutant) cell lines. Results: Two fluorene-triazoles, 1-(2-bromophenyl)-4-(9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO258) and 1-(4-bromophenyl)-4-(2-fluoro-9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO272), both containing bromine substituents, exhibited selective cytotoxicity against MOLM-13, with half-maximal inhibitory concentration (IC50) values of 25.5 μM and 12.5 μM, respectively. Furthermore, LSO258 and LS0272 showed a selectivity index ≥ 2 towards the MOLM-13 cell line. Biaryl hydroxy-1,2,3-triazoles displayed broader activity, with [1,1’-biphenyl]-2-yl(1-(2,5-dibromophenyl)-1H-1,2,3-triazol-4-yl)methanol (LSO278), featuring two bromine groups, demonstrating potency across HCT-116, MDA-MB-231, and MOLM-13 (IC50: 23.4 μM, 34.3 μM, and 18.7 μM, respectively). However, structural rigidity did not consistently predict activity, as 1-(2,5-dibromophenyl)-4-(9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO275), a rigid fluorene-triazole, was inactive. MOLM-13 was the most sensitive cell line, with compounds such as 4-(9H-fluoren-9-yl)-1-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazole (LSO259) and (1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)(4’-fluoro-[1,1’-biphenyl]-2-yl)methanol (LSO280), achieving maximum growth inhibition (MGI > 55%) despite not reaching IC50 values. Conclusions: The results highlight the critical role of bromine substitution on the aryl azide-derived ring in modulating cytotoxic activity. The study reinforces the potential of rigid fluorene-based scaffolds as promising leads for the development of targeted therapies against FLT3-mutant leukemia, aligning with previous reports on 1,2,3-triazole hybrids antiproliferative activity in leukemia models.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Animal Reproduction
- Vol. 20 (1)
Full confluency, serum starvation, and roscovitine for inducing arrest in the G0/G1 phase of the cell cycle in puma skin-derived fibroblast lines
The puma population is constantly decreasing, and cloning by somatic cell nuclear transfer can be used to conserve the species. One of the factors determining the success of the development of cloned embryos is the cell cycle stage of the donor cells. We evaluated the effects of full confluency (~100%), serum starvation (0.5% serum), and roscovitine (15 µM) treatments on the cell cycle synchronization in G0/G1 of puma skin-derived fibroblasts by flow cytometric analysis. Also, we assessed the effects of these synchronization methods on morphology, viability, and apoptosis levels using microscopy tools. The results showed that culturing the cells to confluence for 24 h (84.0%), 48 h (84.6%), and 72 h (84.2%) and serum starvation for 96 h (85.4%) yielded a significantly higher percentage of cells arrested in the G0/G1 (P 0.05) phase than cells not subjected to any cell cycle synchronization method (73.9%). Nevertheless, while serum starvation reduced the percentage of viable cells, no difference was observed for the full confluence and roscovitine treatments (P 0.05). Moreover, roscovitine for 12 h (78.6%) and 24 h (82.1%) was unable to synchronize cells in G0/G1 (P 0.05). In summary, full confluency induces puma fibroblast cell cycle synchronization at the G0/G1 stage without affecting cell viability. These outcomes may be valuable for planning donor cells for somatic cell nuclear transfer in pumas.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Animal Reproduction
- Vol. 20 (1)
Open AccessFull confluency, serum starvation, and roscovitine for inducing arrest in the G0/G1 phase of the cell cycle in puma skin-derived fibroblast lines
The puma population is constantly decreasing, and cloning by somatic cell nuclear transfer can be used to conserve the species. One of the factors determining the success of the development of cloned embryos is the cell cycle stage of the donor cells. We evaluated the effects of full confluency (~100%), serum starvation (0.5% serum), and roscovitine (15 µM) treatments on the cell cycle synchronization in G0/G1 of puma skin-derived fibroblasts by flow cytometric analysis. Also, we assessed the effects of these synchronization methods on morphology, viability, and apoptosis levels using microscopy tools. The results showed that culturing the cells to confluence for 24 h (84.0%), 48 h (84.6%), and 72 h (84.2%) and serum starvation for 96 h (85.4%) yielded a significantly higher percentage of cells arrested in the G0/G1 (P 0.05) phase than cells not subjected to any cell cycle synchronization method (73.9%). Nevertheless, while serum starvation reduced the percentage of viable cells, no difference was observed for the full confluence and roscovitine treatments (P 0.05). Moreover, roscovitine for 12 h (78.6%) and 24 h (82.1%) was unable to synchronize cells in G0/G1 (P 0.05). In summary, full confluency induces puma fibroblast cell cycle synchronization at the G0/G1 stage without affecting cell viability. These outcomes may be valuable for planning donor cells for somatic cell nuclear transfer in pumas.
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , e20548
Characterization of patients with lung adenocarcinoma treated at a reference oncology center in northeastern Brazil and submitted to EGFR gene mutation research.
E20548 Background: Lung cancer has the highest incidence and mortality worldwide. In Brazil, it is the second most common, and individualized therapy, although more efficient than traditional chemotherapy, is still a challenge for health services, especially in developing countries, as socioeconomic disparities make access to genetic testing difficult or treatment. Thus, it is understood that greater knowledge about the genetic profile and therapeutic response of different populations can contribute to policy changes that guarantee expanded access to individualized therapy. Methods: the EGFR gene mutation status was correlated with clinical-epidemiological, socioeconomic, treatment, and survival parameters of patients with lung adenocarcinoma treated from 2014 to 2021 at an oncology referral center in northeastern Brazil. Data were obtained retrospectively from the patient's charts at the Hospital Haroldo Juaçaba/Instituto do Câncer do Ceará. The X²/Fisher and Log-Rank Mantel-Cox tests were used to associate clinical variables and overall survival curves. The Research Ethics Committee approved the research under protocol number 3.544.754. Results: 586 patients tested, 157 (26.8%) had an EGFR mutation, with exon 19 deletion (n = 83, 52.9%). the most frequent followed by L858R (n = 54, 34.4%) and others (n = 30, 12.8%). The EGFR mutation was inversely associated with smoking history (p < 0.001) and previous use of carboplatin plus paclitaxel (p < 0.001). The median overall survival was 33 (95%CI = 25-41) months, and the presence of a mutation was not associated with a worse outcome (p = 0.146). Interestingly, patients with sensitivity mutation who used gefitinib (64.1%) did not show a significant difference in overall survival (p = 0.218). However, when stratifying analyzes according to mutation type, it was observed that patients with exon 19 deletion treated with gefitinib had greater median overall survival (32, 95%CI = 27-37 months) than patients with this mutation not treated with gefitinib (median = 15, 95%CI = 2-25 months) (p < 0.001). Patients with the L858R type sensitivity mutation (p = 0.523) or other mutations (p = 0.439) did not experience significant benefits from gefitinib use. Conclusions: In the population studied, the exon 19 deletion was the most frequent and the only one associated with a substantial benefit from using gefitinib.
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , e20548
Characterization of patients with lung adenocarcinoma treated at a reference oncology center in northeastern Brazil and submitted to EGFR gene mutation research.
E20548 Background: Lung cancer has the highest incidence and mortality worldwide. In Brazil, it is the second most common, and individualized therapy, although more efficient than traditional chemotherapy, is still a challenge for health services, especially in developing countries, as socioeconomic disparities make access to genetic testing difficult or treatment. Thus, it is understood that greater knowledge about the genetic profile and therapeutic response of different populations can contribute to policy changes that guarantee expanded access to individualized therapy. Methods: the EGFR gene mutation status was correlated with clinical-epidemiological, socioeconomic, treatment, and survival parameters of patients with lung adenocarcinoma treated from 2014 to 2021 at an oncology referral center in northeastern Brazil. Data were obtained retrospectively from the patient's charts at the Hospital Haroldo Juaçaba/Instituto do Câncer do Ceará. The X²/Fisher and Log-Rank Mantel-Cox tests were used to associate clinical variables and overall survival curves. The Research Ethics Committee approved the research under protocol number 3.544.754. Results: 586 patients tested, 157 (26.8%) had an EGFR mutation, with exon 19 deletion (n = 83, 52.9%). the most frequent followed by L858R (n = 54, 34.4%) and others (n = 30, 12.8%). The EGFR mutation was inversely associated with smoking history (p < 0.001) and previous use of carboplatin plus paclitaxel (p < 0.001). The median overall survival was 33 (95%CI = 25-41) months, and the presence of a mutation was not associated with a worse outcome (p = 0.146). Interestingly, patients with sensitivity mutation who used gefitinib (64.1%) did not show a significant difference in overall survival (p = 0.218). However, when stratifying analyzes according to mutation type, it was observed that patients with exon 19 deletion treated with gefitinib had greater median overall survival (32, 95%CI = 27-37 months) than patients with this mutation not treated with gefitinib (median = 15, 95%CI = 2-25 months) (p < 0.001). Patients with the L858R type sensitivity mutation (p = 0.523) or other mutations (p = 0.439) did not experience significant benefits from gefitinib use. Conclusions: In the population studied, the exon 19 deletion was the most frequent and the only one associated with a substantial benefit from using gefitinib.
- 29 April 2022
- Published by Wiley in Chemistry & Biodiversity
- Vol. 19 (5) , e202200102
The Isoflavanoid (+)‐PTC Regulates Cell‐Cycle Progression and Mitotic Spindle Assembly in a Prostate Cancer Cell Line
Prostate cancer is the second most common malignancy in men and the development of effective therapeutic strategies remains challenging when more advanced, androgen‐independent or insensitive forms are involved. Accordingly, we have evaluated, using flow cytometry, confocal microscopy and image analysis, the anti‐proliferative effects of (+)‐2,3,9‐trimethoxypterocarpan [(+)‐PTC, 1] on relevant human prostate cancer cells as well as its capacity to control mitosis within them. In particular, the studies reported herein reveal that (+)‐PTC exerts anti‐proliferative activity against the PC‐3 cell lines by regulating cell‐cycle progression with mitosis being arrested in the prophase or prometaphase. Furthermore, it emerges that treatment of the target cells with this compound results in the formation of monopolar spindles, disorganized centrosomes and extensively disrupted γ‐tubulin distributions while centriole replication remains unaffected. Such effects suggest (+)‐PTC should be considered as a possible therapy for androgen‐insensitive/independent prostate cancer.
- 29 April 2022
- Published by Wiley in Chemistry & Biodiversity
- Vol. 19 (5) , e202200102
The Isoflavanoid (+)‐PTC Regulates Cell‐Cycle Progression and Mitotic Spindle Assembly in a Prostate Cancer Cell Line
Prostate cancer is the second most common malignancy in men and the development of effective therapeutic strategies remains challenging when more advanced, androgen‐independent or insensitive forms are involved. Accordingly, we have evaluated, using flow cytometry, confocal microscopy and image analysis, the anti‐proliferative effects of (+)‐2,3,9‐trimethoxypterocarpan [(+)‐PTC, 1] on relevant human prostate cancer cells as well as its capacity to control mitosis within them. In particular, the studies reported herein reveal that (+)‐PTC exerts anti‐proliferative activity against the PC‐3 cell lines by regulating cell‐cycle progression with mitosis being arrested in the prophase or prometaphase. Furthermore, it emerges that treatment of the target cells with this compound results in the formation of monopolar spindles, disorganized centrosomes and extensively disrupted γ‐tubulin distributions while centriole replication remains unaffected. Such effects suggest (+)‐PTC should be considered as a possible therapy for androgen‐insensitive/independent prostate cancer.